Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Limited filings document a foreign private issuer and development-stage biotechnology company reporting through Form 6-K and incorporated reports tied to Form S-8 and Form F-3 registration statements. The filings record ATH434 and MSA development updates, bioMUSE biomarker publications, FDA meeting communications, medical conference presentations, and Appendix 4C quarterly cash flow and activity reports.
Other disclosures cover shareholder meeting and proxy materials, substantial holding notices, share consolidation or split notices, board and governance changes, and capital-structure matters for securities traded as ASX: ATH and NASDAQ: ATHE.
Alterity Therapeutics Limited is implementing a 1 for 50 consolidation of its share capital following shareholder approval at an Extraordinary General Meeting on 29 May 2026. This reduces each holder’s number of shares, with fractional entitlements rounded up to at least one security and the share price adjusted accordingly.
From 3 June to the close of trading on 11 June 2026, Alterity securities trade on the ASX on a post-consolidation, deferred settlement basis under temporary code “ATHDA”, with a record date of 4 June 2026. Listed options “ATHO” and “ATHOA” temporarily trade as “ATHDB” and “ATHDC”. Normal T+2 trading under the “ATH” code resumes on 12 June 2026.
Alterity Therapeutics Limited, a development stage enterprise listed on ASX and Nasdaq, filed a Form 6-K to report an administrative change. The company has changed its registered office address to Level 15, 500 Collins Street, Melbourne, VIC 3000, effective 3 June 2026. The report notes that this Form 6-K is incorporated by reference into several existing Form S-8 and Form F-3 registration statements.
Alterity Therapeutics Limited reports the results of its 2026 Extraordinary General Meeting, confirming that shareholders passed the resolutions presented at the meeting held on 29 May 2026.
The company is a clinical stage biotechnology business focused on disease-modifying therapies for Multiple System Atrophy and related Parkinsonian disorders. Its lead asset, ATH434, has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA and additional positive data in an open label Phase 2 trial in advanced MSA. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA and continues to develop a broader pipeline of patentable compounds targeting neurological disease pathology.
Alterity Therapeutics filed a Form 6-K highlighting new clinical data that support advancing its lead drug candidate ATH434 into a Phase 3 trial for Multiple System Atrophy (MSA), a rare neurodegenerative disease with no approved disease‑modifying therapies.
A 12‑month randomized, double‑blind, placebo‑controlled Phase 2 trial in 77 adults with MSA showed clinically and statistically significant improvement on the modified UMSARS Part I functional scale versus placebo, with consistent trends across additional motor and symptom measures and increased activity captured by wearable sensors. Imaging and biomarker data indicated reduced iron accumulation in affected brain regions and signs of preserved brain volume, and ATH434 was well tolerated with no serious adverse events attributed to the drug.
Alterity also emphasized ongoing work from its bioMUSE natural history study to refine biomarker selection and trial design. ATH434 has Fast Track and Orphan Drug Designations for MSA, and an End‑of‑Phase 2 FDA meeting is planned for mid‑2026 to confirm the Phase 3 development path.
Alterity Therapeutics filed a Form 6-K sharing a new peer‑reviewed publication and pipeline update for its Multiple System Atrophy (MSA) program. The study in NeuroImage shows that quantitative susceptibility mapping (QSM) MRI can detect disease‑specific iron accumulation in MSA, distinguish it from Parkinson’s disease, and track clinical severity, including early‑stage disease.
The research drew on longitudinal bioMUSE Natural History Study data and additional MSA, Parkinson’s and healthy control participants, supporting QSM as an objective imaging biomarker for iron‑modulating therapies such as Alterity’s lead candidate ATH434. Alterity notes that ATH434 showed robust clinical efficacy, target engagement and a favorable safety profile in Phase 2 trials and has Fast Track and Orphan Drug Designations. The company is advancing ATH434 toward a pivotal Phase 3 trial in MSA and plans an End‑of‑Phase 2 meeting with the FDA in mid‑2026.
Alterity Therapeutics Limited reports that presentations on its development program for Multiple System Atrophy (MSA) will be delivered at several medical conferences in May 2026. These include the International Society for Magnetic Resonance in Medicine annual meeting, the Movement Disorder Society of Australia and New Zealand meeting, and the MSA Symposium 2026.
The company describes itself as a clinical stage biotechnology firm focused on disease modifying therapies for MSA and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA. Its lead asset, ATH434, has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open label Phase 2 trial in advanced MSA.
Alterity Therapeutics reported its Q3 FY26 cash flow and corporate update, highlighting progress toward a Phase 3 trial of ATH434 for Multiple System Atrophy (MSA). The company received written Type C feedback from the U.S. FDA on clinical pharmacology, non-clinical, and CMC elements, supporting its pivotal development plans and an End-of-Phase 2 meeting targeted for mid-2026.
New analyses from the ATH434-201 Phase 2 trial using the MuSyCA composite scale showed ATH434 slowed disease progression versus placebo, with treatment effects of −1.9 points at 75 mg and −4.0 points at 50 mg (p=0.034, 41% relative effect) at Week 52. Alterity strengthened its team by appointing Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor and Ann Cunningham as an independent Non-Executive Director.
The company reported cash and cash equivalents of A$44.53 million as of 31 March 2026 and operating cash outflows of A$4.73 million for the quarter, implying about 9.4 quarters of funding at the current burn rate. Management continues strategic partnering discussions for ATH434 and active engagement with investors and medical key opinion leaders.
ALTERITY THERAPEUTICS LTD director Ann Michelle Cunningham has filed an initial Form 3 insider ownership report. The filing lists her as a director but shows no reported transactions or derivative positions, indicating this is a baseline disclosure of her status rather than an update to prior trading activity.